Quick Reference: Standard Protocol Community-documented protocol: 250 mcg subcutaneous in the morning, 3 days per week, for 8-week cycles -- far below the 2.4 mg weekly clinical trial dose, reflecting conservative research-peptide practice
20 JiangX
[23] Pereira BA, Zangeronimo MG, Castillo-Martn M, Gadani B, Chaves BR, Rodrguez-Gil JE, et al
CJC-1295 Ipamorelin vs TRT, Which Do You Need
The sites dosage calculator and glossary explain how half-life relates to dosing intervals in general terms
This is the central regulatory problem that full FDA approval would need to solve and it is the reason PCAC reviews for peptides like BPC-157 often hinge on available safety data rather than efficacy evidence from controlled human studies